// App-Quantinova.ai

e21649 : Evaluation of chemotherapy-induced nausea and vomiting (CINV) events and associated resource utilization for CINV in patients(pts) treated with highly emetogenic chemotherapy (HEC) and carboplatin (Carbo) and palonosetron (palo)-based anti-emetic regimens.

Researchers

Presenter

  • Robert B. Geller

Principal Investigators

  • Stanley M. Marks

  • Nashat Y. Gabrail

  • Lincy S. Lal

  • Urvi Mujumdar

  • Lee Steven Schwartzberg

Medical Centers

  • Berlin Memor Hosp, Appleton, WI

  • University of Pittsburgh Cancer Institute, Pittsburgh, PA

  • Gabrail Cancer Center, Canton, OH

  • Cardinal Health, Dallas, TX

  • West Clinic, Memphis, TN

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chemotherapy-induced nausea and vomiting

Biomarkers

  • NDC80 Kinetochore Complex Component

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Palonosetron

  • Carboplatin

  • Cisplatin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved